NEWLINK GENETICS CORP Form 8-K April 25, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2018

NewLink Genetics Corporation (Exact name of registrant as specified in its charter)

Delaware001-3534242-1491350(State or other jurisdiction(Commission (IRS Employerof incorporation)File Number) Identification No.)

2503 South Loop Drive 50010 Ames, IA (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (515) 296-5555

Not applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Section 8 - Other Events

Item 8.01. Other Events.

On April 25, 2018, NewLink Genetics Corporation issued a press release titled "NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting."

A copy of the press release is attached hereto as Exhibits 99.1 and is incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description

99.1 Press Release, dated April 25, 2018, entitled <u>"NewLink Genetics Announces Presentation of Abstracts</u> at ASCO 2018 Annual Meeting."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 25, 2018

NewLink Genetics Corporation

By:/s/ John B. Henneman III John B. Henneman III Its: Chief Financial Officer